Clinical and pharmacological hallmarks of rifapentine’s use in diabetes patients with active and latent tuberculosis: do we know enough?

Clinical and pharmacological hallmarks of rifapentine’s use in diabetes patients with active and latent tuberculosis: do we know enough?

Chunlan Zheng,1,* Xiufen Hu,2,* Li Zhao,1 Minhui Hu,1 Feng Gao3 1Department of Internal Medicine – Section 5, Wuhan Pulmonary Hospital (Wuhan Tuberculosis Control Institute), 2Department of Paediatrics, Tongji Hospital, 3Department of Endocrinology, Union Hospital, Tongji Medical College,...

Full description

Bibliographic Details
Main Authors: Zheng C, Hu X, Zhao L, Hu M, Gao F
Format: Article
Language:English
Published: Dove Medical Press 2017-10-01
Series:Drug Design, Development and Therapy
Subjects:
rifamycin
antituberculosis treatment
glucose intolerance
hyperglycemia
Online Access:https://www.dovepress.com/clinical-and-pharmacological-hallmarks-of-rifapentiners-use-in-diabete-peer-reviewed-article-DDDT

Internet

https://www.dovepress.com/clinical-and-pharmacological-hallmarks-of-rifapentiners-use-in-diabete-peer-reviewed-article-DDDT

Similar Items